Homepage
Palvella Therapeutics is a clinical-stage biopharmaceutical company specializing in developing medicines for patients with rare dermatological diseases with no approved therapies. Its QTORIN platform delivers topical rapamycin-based treatments, with its lead candidate in Phase 3 trials for microcystic lymphatic malformations and Phase 2 for cutaneous venous malformations.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2026
Dec 2024
Jan 2023
Dec 2022
May 2020
Dec 2018
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Biopharmaceutical company developing sustained-release hydrogel therapies targeting retinal disea...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
